PDF(Pubmed)
Abstract：
In recent years, microRNAs (miRNAs) have garnered increasing attention for their potential implications in cancer pathogenesis, functioning either as oncogenes or tumor suppressors. Notably, angiosarcoma, along with various other cardiovascular tumors such as lipomas, rhabdomyomas, hemangiomas, and myxomas, has shown variations in the expression of specific miRNA subtypes. A substantial body of evidence underscores the pivotal involvement of miRNAs in the genesis of angiosarcoma and certain cardiovascular tumors. This review aims to delve into the current literature on miRNAs and their prospective applications in cardiovascular malignancies, with a specific focus on angiosarcoma. It comprehensively covers diagnostic methods, prognostic evaluations, and potential treatments while providing a recapitulation of angiosarcoma\'s risk factors and molecular pathogenesis, with an emphasis on the role of miRNAs. These insights can serve as the groundwork for designing randomized control trials, ultimately facilitating the translation of these findings into clinical applications. Moving forward, it is imperative for studies to thoroughly scrutinize the advantages and disadvantages of miRNAs compared to current diagnostic and prognostic approaches in angiosarcoma and other cardiovascular tumors. Closing these knowledge gaps will be crucial for harnessing the full potential of miRNAs in the realm of angiosarcoma and cardiovascular tumor research.
摘要：
近年来,microRNAs（miRNAs）因其在癌症发病机制中的潜在影响而受到越来越多的关注。作为癌基因或肿瘤抑制因子。值得注意的是,血管肉瘤,以及各种其他心血管肿瘤，如脂肪瘤，横纹肌瘤,血管瘤,还有粘液瘤,已显示特定miRNA亚型的表达变化。大量证据强调了miRNA在血管肉瘤和某些心血管肿瘤的发生中的关键参与。这篇综述旨在深入研究当前关于miRNAs及其在心血管恶性肿瘤中的未来应用的文献。特别关注血管肉瘤。它全面涵盖了诊断方法，预后评估，和潜在的治疗方法，同时提供血管肉瘤的危险因素和分子发病机制的概述，强调miRNA的作用。这些见解可以作为设计随机对照试验的基础，最终促进这些发现转化为临床应用。往前走,与目前在血管肉瘤和其他心血管肿瘤中的诊断和预后方法相比，研究必须彻底审查miRNAs的优缺点。缩小这些知识差距对于在血管肉瘤和心血管肿瘤研究领域利用miRNA的全部潜力至关重要。
